Overview

• Resalis Therapeutics presented preclinical results for RES-010, an antisense oligonucleotide that blocks miR-22 to alter fat use and mitochondrial activity.
• Obese mice given weekly RES-010 lost weight despite unchanged food intake and did not regain after stopping; non-human primate studies suggested greater fat loss with less lean-mass loss than semaglutide.
• A randomized, placebo-controlled Phase 1 study in the Netherlands is under way with up to 80 participants to assess safety, with first readouts expected in early 2026.
• Separate EASD research in The Lancet reported that 79% of 10–17-year-olds with type 2 diabetes on tirzepatide were below the diabetes threshold after 30 weeks, with clinically meaningful BMI reductions.
• Eli Lilly said oral orforglipron reduced HbA1c by 2.2% versus 1.4% for oral semaglutide and produced greater average weight loss over one year in adults with type 2 diabetes.